Parabilis Medicines, a Phase 3-ready biotech developing engineered peptide therapies for cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
Parabilis Medicines is a clinical-stage biotech developing medicines that target proteins previously considered undruggable. Its proprietary Helicon platform produces stabilized helical peptides designed to modulate intracellular protein interactions that are inaccessible to traditional small molecules or biologics. Its lead candidate, zolucatetide, targets the Wnt/β-catenin pathway, which drives a broad range of solid tumors; in desmoid tumors, zolucatetide has demonstrated tumor reductions in 100% of patients and a 74% objective response rate across over 150 patients evaluated to date. The company plans to initiate a Phase 3 registrational trial in desmoid tumors in the first half of 2027.
The Cambridge, MA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol PBLS. Parabilis Medicines filed confidentially on April 2, 2026. Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, and LifeSci Capital are the joint bookrunners on the deal.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.